Articles dans des revues avec comité de lecture (368)
58.
Dreyling, M., Vitolo, U., Hiemeyer, F., Giurescu, M., Garcia-Vargas, J., Gorbatchevsky, I., Liu, L., Koechert, K., Peña, C., Neves, M., Childs, B. B., Morschhauser, F., Zinzani, P. P., Bouabdallah, K., Bron, D., Cunningham, D., Assouline, S. S., Verhoef, G. E. G., Linton, K., & Thieblemont, C. (2017). Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. Annals of oncology, 28(9), 2169-2178. doi:10.1093/annonc/mdx28959.
Fayyad Kazan, H., Fayyad Kazan, M., Badran, B., Bron, D., Lagneaux, L., & Najar, M. (2017). Study of the microRNA expression profile of foreskin derived mesenchymal stromal cells following inflammation priming. Journal of translational medicine, 15(1), 10. doi:10.1186/s12967-016-1106-360.
Libert, Y., Borghgraef, C., Beguin, Y., Delvaux, N., DeVos, M., Doyen, C., Dubruille, S., Etienne, A.-M., Liénard, A., Merckaert, I., Reynaert, C., Slachmuylder, J.-L., Straetmans, N., Van Den Neste, E., Bron, D., & Razavi, D. (2017). Factors associated with self-perceived burden to the primary caregiver in older patients with hematologic malignancies: An exploratory study. Psycho-oncology, 26(1), 118-124. doi:10.1002/pon.410861.
Pistone, A., Maerevoet, M., Wittnebel, S., Vercruyssen, M., Spilleboudt, C., Buntinx, S., Bron, D., & Meuleman, N. (2016). Early Discontinuation of Lenalidomide in Patients with Relapsing or Refractory Multiple Myeloma: Predictive Factors for Stopping in the Real Life. Blood, 128(22), 4504-4504. doi:10.1182/blood.V128.22.4504.450463.
Najar, M., Fayyad Kazan, M., Fayyad Kazan, H., Meuleman, N., Bron, D., & Lagneaux, L. (2016). Data on nitric oxide production by human bone marrow-derived mesenchymal stromal cells. Data in brief, 8, 1111-1114. doi:10.1016/j.dib.2016.07.02164.
Green, T., Muckenthaler, M. M., Smand, C., Sonneveld, P., Bron, D., Chomienne, C., de Wit, T. D., de Haas, F., Engert, A., Hagenbeek, A., Jäger, U., & MacIntyre, E. (2016). Costs of haematological disease high and rising. The Lancet Haematology, 3(8), e353-e354. doi:10.1016/S2352-3026(16)30074-665.
Libert, Y., Dubruille, S., Borghgraef, C., Etienne, A.-M., Merckaert, I., Paesmans, M., Reynaert, C., Roos, M., Slachmuylder, J.-L., Vandenbossche, S., Bron, D., & Razavi, D. (2016). Vulnerabilities in older patients when cancer treatment is initiated: Does a cognitive impairment impact the two-year survival? PloS one, 11(8), e0159734. doi:10.1371/journal.pone.015973467.
Roufosse, F., Heimann, P., Lambert, F., Sidon, P., Bron, D., Cottin, V., & Cordier, J.-F. (2016). Severe prolonged cough as presenting manifestation of fip1l1-pdgfra + chronic eosinophilic leukaemia: A widely ignored association. Respiration, 91(5), 374-379. doi:10.1159/00044607668.
Demeestere, I., Brice, P., Peccatori, F. A., Kentos, A., Dupuis, J., Zachée, P., Casasnovas, O., Van Den Neste, E., Dechene, J., De Maertelaer, V., Bron, D., & Englert, Y. (2016). No Evidence for the Benefit of Gonadotropin-Releasing Hormone Agonist in Preserving Ovarian Function and Fertility in Lymphoma Survivors Treated With Chemotherapy: Final Long-Term Report of a Prospective Randomized Trial. Journal of clinical oncology, 34(22), Selected for editorial, 2568-74. doi:10.1200/JCO.2015.65.886469.
Kourie Hampig, R., Ameye, L., Paesmans, M., & Bron, D. (2016). Improved Survival of Calreticulin-Mutated Patients Compared with Janus Kinase 2 in Primary Myelofibrosis: A Meta-Analysis. Clinical Lymphoma, Myeloma and Leukemia, 16(5), 264-268. doi:10.1016/j.clml.2016.01.009